vs
芝商所（CME）与福泰制药（VRTX）财务数据对比。点击上方公司名可切换其他公司
福泰制药的季度营收约是芝商所的1.7倍（$3.2B vs $1.9B），福泰制药净利率更高（37.3% vs 0.1%，领先37.3%），芝商所同比增速更快（14.5% vs 9.5%），过去两年芝商所的营收复合增速更高（10.8% vs 8.9%）
芝商所是总部位于美国伊利诺伊州芝加哥的金融服务企业，为全球规模最大的金融衍生品交易所运营商，旗下拥有芝加哥商品交易所、芝加哥期货交易所、纽约商业交易所、纽约商品交易所等交易平台，覆盖农产品、货币、能源等品类交易，同时持有标普道琼斯指数27%的股权。
福泰制药是总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略、而非组合化学方法开发药物的生物技术公司之一。除波士顿总部外，公司还在加州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心。
CME vs VRTX — 直观对比
营收规模更大
VRTX
是对方的1.7倍
$1.9B
营收增速更快
CME
高出4.9%
9.5%
净利率更高
VRTX
高出37.3%
0.1%
两年增速更快
CME
近两年复合增速
8.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $3.2B |
| 净利润 | $1.2M | $1.2B |
| 毛利率 | — | 85.4% |
| 营业利润率 | 0.1% | 37.8% |
| 净利率 | 0.1% | 37.3% |
| 营收同比 | 14.5% | 9.5% |
| 净利润同比 | 20.7% | 30.5% |
| 每股收益（稀释后） | — | $4.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMEVRTX
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.5B | $3.1B | ||
| Q2 25 | $1.7B | $3.0B | ||
| Q1 25 | $1.6B | $2.8B | ||
| Q4 24 | $1.5B | $2.9B | ||
| Q3 24 | $1.6B | $2.8B | ||
| Q2 24 | $1.5B | $2.6B |
净利润CMEVRTX
| Q1 26 | $1.2M | — | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $908.0M | $1.1B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $956.2M | $646.3M | ||
| Q4 24 | $874.6M | $913.0M | ||
| Q3 24 | $912.8M | $1.0B | ||
| Q2 24 | $883.2M | $-3.6B |
毛利率CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | — | 85.8% | ||
| Q2 24 | — | 85.9% |
营业利润率CMEVRTX
| Q1 26 | 0.1% | — | ||
| Q4 25 | 61.8% | 37.8% | ||
| Q3 25 | 63.3% | 38.6% | ||
| Q2 25 | 66.7% | 38.8% | ||
| Q1 25 | 67.5% | 22.7% | ||
| Q4 24 | 62.1% | 35.2% | ||
| Q3 24 | 64.6% | 40.3% | ||
| Q2 24 | 65.3% | -132.9% |
净利率CMEVRTX
| Q1 26 | 0.1% | — | ||
| Q4 25 | 71.7% | 37.3% | ||
| Q3 25 | 59.1% | 35.2% | ||
| Q2 25 | 60.6% | 34.8% | ||
| Q1 25 | 58.2% | 23.3% | ||
| Q4 24 | 57.3% | 31.4% | ||
| Q3 24 | 57.6% | 37.7% | ||
| Q2 24 | 57.6% | -135.8% |
每股收益（稀释后）CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | $3.24 | $4.64 | ||
| Q3 25 | $2.49 | $4.20 | ||
| Q2 25 | $2.81 | $3.99 | ||
| Q1 25 | $2.62 | $2.49 | ||
| Q4 24 | $2.40 | $3.62 | ||
| Q3 24 | $2.50 | $4.01 | ||
| Q2 24 | $2.42 | $-13.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $6.6B |
| 总债务越低越好 | $3.4B | — |
| 股东权益账面价值 | — | $18.7B |
| 总资产 | $202.0B | $25.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CMEVRTX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $4.5B | $6.6B | ||
| Q3 25 | $2.6B | $6.3B | ||
| Q2 25 | $2.1B | $6.4B | ||
| Q1 25 | $1.5B | $6.2B | ||
| Q4 24 | $3.0B | $6.1B | ||
| Q3 24 | $2.4B | $6.5B | ||
| Q2 24 | $1.9B | $5.8B |
总债务CMEVRTX
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | $28.7B | $18.7B | ||
| Q3 25 | $28.2B | $17.3B | ||
| Q2 25 | $27.7B | $17.2B | ||
| Q1 25 | $27.0B | $16.5B | ||
| Q4 24 | $26.5B | $16.4B | ||
| Q3 24 | $28.2B | $15.6B | ||
| Q2 24 | $27.6B | $14.8B |
总资产CMEVRTX
| Q1 26 | $202.0B | — | ||
| Q4 25 | $198.4B | $25.6B | ||
| Q3 25 | $187.1B | $24.9B | ||
| Q2 25 | $179.9B | $24.0B | ||
| Q1 25 | $157.8B | $22.9B | ||
| Q4 24 | $137.4B | $22.5B | ||
| Q3 24 | $137.8B | $22.2B | ||
| Q2 24 | $123.4B | $20.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $498.0M |
| 自由现金流经营现金流 - 资本支出 | — | $348.6M |
| 自由现金流率自由现金流/营收 | — | 10.9% |
| 资本支出强度资本支出/营收 | — | 4.7% |
| 现金转化率经营现金流/净利润 | — | 0.42× |
| 过去12个月自由现金流最近4个季度 | — | $3.2B |
8季度趋势，按日历期对齐
经营现金流CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $498.0M | ||
| Q3 25 | $968.1M | $1.2B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $1.1B | $818.9M | ||
| Q4 24 | $1.0B | $584.6M | ||
| Q3 24 | $1.0B | $1.4B | ||
| Q2 24 | $776.9M | $-3.8B |
自由现金流CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $348.6M | ||
| Q3 25 | $949.7M | $1.1B | ||
| Q2 25 | $1.0B | $927.4M | ||
| Q1 25 | $1.1B | $778.2M | ||
| Q4 24 | $991.7M | $492.0M | ||
| Q3 24 | $973.2M | $1.3B | ||
| Q2 24 | $758.7M | $-3.8B |
自由现金流率CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | 66.8% | 10.9% | ||
| Q3 25 | 61.8% | 37.0% | ||
| Q2 25 | 61.5% | 31.3% | ||
| Q1 25 | 67.1% | 28.1% | ||
| Q4 24 | 65.0% | 16.9% | ||
| Q3 24 | 61.4% | 47.0% | ||
| Q2 24 | 49.5% | -144.5% |
资本支出强度CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 4.7% | ||
| Q3 25 | 1.2% | 3.3% | ||
| Q2 25 | 1.1% | 4.9% | ||
| Q1 25 | 0.9% | 1.5% | ||
| Q4 24 | 1.7% | 3.2% | ||
| Q3 24 | 1.9% | 2.4% | ||
| Q2 24 | 1.2% | 2.6% |
现金转化率CMEVRTX
| Q1 26 | — | — | ||
| Q4 25 | 0.96× | 0.42× | ||
| Q3 25 | 1.07× | 1.15× | ||
| Q2 25 | 1.03× | 1.04× | ||
| Q1 25 | 1.17× | 1.27× | ||
| Q4 24 | 1.16× | 0.64× | ||
| Q3 24 | 1.10× | 1.31× | ||
| Q2 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CME
暂无分部数据
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
